Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 11/20 | 0.55 |
| ▸ | PIM2 | Q9P1W9 | 10/20 | 0.55 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.54 |
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.53 |
| ▸ | IGF1R | P08069 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1125013 | 0.72 | PIM1 (0.72) | PIM1PIM2PIM3HPGDAKR1B1 | |
| SCHEMBL1125015 | 0.72 | PIM1 (0.72) | PIM1PIM2PIM3HPGDAKR1B1 | |
| SCHEMBL2555241 | 0.72 | PIM1 (0.72) | PIM1PIM2PIM3HPGDAKR1B1 | |
| SCHEMBL1250387 | 0.72 | PIM1 (1.00) | PIM1PIM2PIM3HPGDAKR1B1 | |
| SCHEMBL4862893 | 0.72 | PIM1 (0.72) | PIM1PIM2PIM3HPGDAKR1B1 | |
| SCHEMBL2132747 | 0.72 | PIM1 (1.00) | PIM1PIM2PIM3HPGDAKR1B1 | |
| SCHEMBL211085 | 0.72 | PIM1 (1.00) | PIM1PIM2PIM3HPGDAKR1B1 | |
| SCHEMBL4862901 | 0.72 | PIM1 (0.72) | PIM1PIM2PIM3HPGDAKR1B1 | |
| SCHEMBL2539685 | 0.71 | PIM1 (1.00) | PIM1PIM2PIM3HPGDAKR1B1 | |
| SCHEMBL2539691 | 0.71 | PIM1 (1.00) | PIM1PIM2PIM3HPGDAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022716-B2 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2003-07-31 | — | — | US | disclosed |
| US-6525202-B2 | E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination | WYETH | 2003-02-25 | — | — | US | disclosed |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | PIM1 4057/4885PIM2 3864/4885PIM3 3388/4885 |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | PIM1 4057/4885PIM2 3864/4885PIM3 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.